AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AROVELLA THERAPEUTICS LTD

0.047

-0.001-2.08%

Volume:167.09K

Turnover:8K

Market Cap:56.81M

PE:-8.10

High:0.048

Open:0.048

Low:0.047

Close:0.048

52wk High:0.102

52wk Low:0.046

Shares:1.21B

Float Shares:895.86M

Volume Ratio:1.18

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.006

EPS(LYR):-0.006

ROE:-40.41%

ROA:-26.35%

PB:4.01

PE(LYR):-8.10

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Arovella Therapeutics Says Second Clinical Batch of ALA-101 Manufactured and Released

MT Newswires Live

Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

THOMSON REUTERS

Charles River Laboratories International Inc: to Perform Viral Safety Release Testing on Clinical Batches of Ala-101

THOMSON REUTERS

Charles River to Provide GMP NGS Testing Services to Arovella Therapeutics Under New Collaboration

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/ALA.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.047,"timestamp":1791421260390,"preClose":0.048,"halted":0,"volume":167093,"delay":0,"changeRate":-0.020833333333333353,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1208783672,"eps":-0.0058,"marketStatus":"Trading","change":-0.001,"latestTime":"10-08 12:09:27 AEDT","open":0.048,"high":0.048,"low":0.047,"amount":7855,"amplitude":0.020833,"askPrice":0.048,"askSize":72051,"bidPrice":0.047,"bidSize":109659,"shortable":3,"etf":0,"ttmEps":-0.0058,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.048,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.179456,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ALA.AU","preClose":0.048,"auctionPrice":0.048,"auctionVolume":1927,"auctionTime":1791413941561,"referenceTime":1791369003092,"auction":1,"marketStatus":"盘前竞价","timestamp":1791413941561}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-26.35%","roe":"-40.41%","lyrEps":-0.0058,"volumeRatio":1.179456,"shares":1208783672,"dividePrice":0,"high":0.048,"amplitude":0.020833,"preClose":0.048,"low":0.047,"week52Low":0.046,"pbRate":"4.01","psRate":"16.24","week52High":0.102,"institutionHeld":0,"latestPrice":0.047,"committee":0.206967,"eps":-0.0058,"divideRate":0,"volume":167093,"delay":0,"ttmEps":-0.0058,"open":0.048,"prevYearClose":0.093,"prevWeekClose":0.047,"prevMonthClose":0.048,"prevQuarterClose":0.048,"fiveDayClose":0.047,"twentyDayClose":0.061,"sixtyDayClose":0.065},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673062351","title":"Arovella Therapeutics Says Second Clinical Batch of ALA-101 Manufactured and Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062351","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673062351?lang=en_us&edition=fundamental","pubTime":"2026-10-07 10:29","pubTimestamp":1791340181,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  said a second clinical batch of ALA-101, its cell therapy for blood cancers, has been manufactured and released, according to a Wednesday filing on the Australian bourse.The company added that a third batch, which it expects to release by the end of December, is anticipated to provide enough material to complete the phase 1 trial of 46 patients across five hospital sites.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LABX","BK4139","BK4539","LENZ","BK7096","ALA","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119902","title":"Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119902?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRL","LU0757428866.USD","BK4585","IE00BFMHRM44.USD","BK4530","LU1815336091.USD","BK7096","LU0029874061.USD","LU0128526141.USD","BK4588","LU0390134368.USD","ALA.AU","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119191","title":"Charles River Laboratories International Inc: to Perform Viral Safety Release Testing on Clinical Batches of Ala-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119191?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:02","pubTimestamp":1783944143,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0128526141.USD","BK7096","BK4121","LU0029874061.USD","LU0757428866.USD","IE00BFMHRM44.USD","BK4585","BK4530","BK4588","LU0390134368.USD","CRL","ALA.AU","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651211993","title":"Charles River to Provide GMP NGS Testing Services to Arovella Therapeutics Under New Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2651211993","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651211993?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:01","pubTimestamp":1783944066,"startTime":"0","endTime":"0","summary":"Charles River to provide GMP NGS testing services to Arovella Therapeutics under new collaborationCharles River entered a collaboration with Arovella Therapeutics to provide GMP next-generation sequen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL4DdDks:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0390134368.USD","CRL","ALA.AU","LU0128526141.USD","LU1815336091.USD","LU0029874061.USD","BK4121","LU0757428866.USD","IE00BFMHRM44.USD","BK4588","BK4530","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALA.AU\",params:#limit:6,delay:true,,,undefined,":[]}}